Loading...
•
Dec 31, 2020
Shattuck Labs Q4 2020 Earnings Report
Reported fourth quarter and full year financial results and provided recent business highlights.
Key Takeaways
Shattuck Labs reported financial results for the fourth quarter and full year ended December 31, 2020. The company's cash and cash equivalents and short-term investments were $335.4 million as of December 31, 2020, and believes this will be sufficient to fund operations through 2024.
Continued Enrollment of Phase 1 Clinical Trial of SL-172154 in Ovarian Cancer
Initiated Enrollment of Phase 1 Clinical Trial of SL-172154 in Head and Neck or Skin Squamous Cell Carcinoma
Continued Enrollment of Phase 1 Clinical Trial of SL-279252
Completed Initial Public Offering (IPO)
Forward Guidance
Shattuck believes its cash and cash equivalents and short-term investments will be sufficient to fund its operations through 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...